Government of India issues advisory on GLP-1 drugs to curb unsupervised sales

Exam-focused facts from the 2 April 2026 current affairs briefing.

Key facts

GLP-1 drugs are prescription-only and can be prescribed only by endocrinologists, cardiologists, and internal medicine specialists.
Over-the-counter sales of GLP-1 drugs are prohibited.
The Drug Controller General of India (DCGI) has intensified inspections with State Drug Controllers and warned of license cancellation, fines, and legal action for non-compliance.
Common GLP-1 drugs available in India include Semaglutide (injection and oral), Liraglutide, Tirzepatide, Dulaglutide, and Exenatide.
An advisory issued on March 10, 2026 bans misleading advertisements and mandates nationwide inspections of pharmacies, clinics, and warehouses.